loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations

Gufic BioSciences Results: Latest Quarterly Results & Analysis

Open Free Trading Account Online with ICICIDIRECT
+91
Gufic BioSciences Ltd. 01 Jun 2026 14:35 PM

Q4FY26 & FY26 Result Announced for Gufic BioSciences Ltd.

Pharmaceuticals company Gufic BioSciences announced Q4FY26 & FY26 results

Consolidated Financial Highlights:

  • Consolidated Total Income for Q4FY26 stood at Rs 25,064.59 lakh, representing a QoQ increase of 7.94% compared to Rs 23,220.04 lakh in Q3FY26 and a YoY increase of 22.02% from Rs 20,541.46 lakh in Q4FY25.
  • Consolidated Revenue from operations for Q4FY26 was Rs 25,181.97 lakh, showing a QoQ growth of 8.82% from Rs 23,140.99 lakh and a YoY growth of 22.83% from Rs 20,502.01 lakh.
  • Consolidated Net Profit for Q4FY26 was recorded at Rs 2,189.61 lakh, a significant QoQ increase of 76.24% from Rs 1,242.36 lakh and a YoY increase of 183.64% from Rs 771.95 lakh in Q4FY25.
  • Consolidated Revenue from operations for the full year FY26 reached Rs 94,400.66 lakh, marking a 15.15% increase from Rs 81,980.59 lakh in FY25.
  • Consolidated Total Income for FY26 was Rs 94,666.40 lakh, an increase of 14.97% compared to Rs 82,343.24 lakh in FY25.
  • The Consolidated Net Profit for the full year FY26 stood at Rs 6,421.27 lakh, showing a decrease of 7.80% compared to Rs 6,964.87 lakh in FY25.
  • Consolidated Total Comprehensive Income for FY26 was Rs 6,471.40 lakh, compared to Rs 6,952.18 lakh in FY25.

Standalone Financial Results:

  • Standalone Total Income for Q4FY26 was Rs 25,085.65 lakh, registering a QoQ increase of 8.18% from Rs 23,188.68 lakh and a YoY increase of 22.13% from Rs 20,540.31 lakh.
  • Standalone Revenue from operations for Q4FY26 stood at Rs 25,205.23 lakh, up 9.07% QoQ from Rs 23,109.36 lakh and up 22.94% YoY from Rs 20,502.01 lakh.
  • The company reported a Standalone Net Profit of Rs 2,057.44 lakh in Q4FY26, representing a QoQ growth of 32.19% from Rs 1,556.39 lakh and a YoY growth of 158.00% compared to Rs 797.41 lakh in Q4FY25.
  • For the full year FY26, Standalone Revenue from operations reached Rs 94,047.54 lakh, a 14.72% YoY increase from Rs 81,980.59 lakh in FY25.
  • Standalone Total Income for FY26 was Rs 94,305.75 lakh, up 14.53% from Rs 82,342.09 lakh in FY25.
  • Standalone Net Profit for the full year FY26 was Rs 6,314.87 lakh, a decline of 9.70% from Rs 6,993.28 lakh in FY25.
  • Standalone Total Comprehensive Income for FY26 was Rs 6,364.80 lakh, compared to Rs 6,980.51 lakh in FY25.

Business Highlights:

  • Segment-wise Performance: The Group's business activity falls within a single operating segment, which is Pharmaceuticals.
  • Dividend Recommendation: The Board of Directors has recommended a final dividend of Re 0.10/- per equity share (i.e., @ 10% on the face value of Rs 1/- each) for FY26, subject to shareholder approval.
  • Auditor Opinion: The Statutory Auditors have issued an Audit Report with an unmodified opinion on the Audited Financial Results (Standalone and Consolidated) for FY26.
  • Tax Concession: During the year, the company opted for the concessional tax regime under section 115BAA of the Income Tax Act, 1961, and consequently restated the deferred tax assets/liabilities on account of change in tax rates.

Result PDF

Pharmaceuticals company Gufic BioSciences announced Q3FY26 results

  • Total Income: Rs 231.1 crore against Rs 230.4 crore during Q3FY25, change 0%.
  • EBITDA: Rs 37.1 crore against Rs 37.9 crore during Q3FY25, change -2%.
  • EBITDA Margin: 16.05% for Q3FY26.
  • PBT: Rs 21.1 crore against Rs 20.5 crore during Q3FY25, change 3%.
  • PBT Margin: 9.13% for Q3FY26.
  • PAT: Rs 15.6 crore against Rs 14.9 crore during Q3FY25, change 5%.
  • PAT Margin: 6.75% for Q3FY26.

Result PDF

Pharmaceuticals firm Gufic BioSciences announced Q1FY23 Result :

  • Critical Care Division:
    • Retained leadership position in Anti fungals & Anti bacterials
    • Launch of Dual Chamber Bag initially targeting Anti-infectives. Addressable market size is ~Rs. 3,000 crores
    • Critical Care segment faced headwinds due to reduced hospitalization and excess inventory in the channel. With the launch of Dual Chamber Bags and normalization of hospitalization we see growth coming back in the next few quarters
    • Entered Neurology with unique products, with a special task force, and dedicated training center to broaden the addressable market
  • Ferticare Division:
    • Dydrogesterone: This product is ready for launch. To de-risk, we have vertically integrated with our own API. Market size for this product is ~Rs. 700 crores growing at 60% YoY. We as a Company are planning annual sales of Rs. 20 Crs. in less than 2 years
    • Gufic has invested to develop recombinant alternatives to the urinary source of certain hormones which are critical in the treatment of infertility and thereby ensuring we will be independent of geopolitical as well as currency exchange risks and potential pitfalls in the next 15-18 months
    • Having the widest basket of products along with vertically integrated manufacturing and strong field presence, we intend to be among the top 3 players in the next 3 years in infertility market that is around ~Rs. 4,000 Crs. and growing at 15%

 

Result PDF

Pharmaceuticals company Gufic BioSciences declares Q3FY22 result:

  • The Non-CoVID portfolio of Criticare Group has shown strong growth fueled by Penem Portfolio (Doripenem, Ertapenem, Meropenem, Imipenem & Faropenem) and the Anti Fungal portfolio (Micafungin, Caspofungin & Anidulafungin)
  • Core Infertility Portfolio has nearly doubled. We have seen healthy growth in this portfolio even when compared to the pre-pandemic period due to certain changes in strategies
  • Herbal Products – Launched a new range of Multi-Vitamins which has led to high growth in this segment
  • Spark Division – A new product portfolio will be launched under the Cardiac Diabetic Management in Q2 FY23
  • Stellar – The division was launched last year, and we are seeing good traction in this segment. We plan to launch 6 to 8 new products in the coming six months
  • Aesthaderm – Stunnox has registered strong growth and continues to see positive trends. This would be one of the pillar brands going ahead

 

Result PDF

Disclaimer – I ICICI Securities Ltd. ( I-Sec). Registered office of I-Sec is at ICICI Securities Ltd. - ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025, India, Tel No : 022 - 6807 7100. I-Sec is acting as a distributor to solicit bond related products. All disputes with respect to the distribution activity, would not have access to Exchange investor redressal forum or Arbitration mechanism. The contents herein above shall not be considered as an invitation or persuasion to trade or invest. I-Sec and affiliates accept no liabilities for any loss or damage of any kind arising out of any actions taken in reliance thereon. Investments in securities market are subject to market risks, read all the related documents carefully before investing. The contents herein mentioned are solely for informational and educational purpose.
Download App

Download Our App

Get it on google Play Store Download on the App Store
market app